Furthermore, our results may allow us to test whether engineering the IFN-γR/JAK1/STAT1 signaling pathway in APCs could be of value in achieving a more efficient presentation of endogenous tumor–associated peptides to CD4+ T cells and potentially enhancing tumor responses. Here, JAK1 is linked to neoplasm.